AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

JCR Pharmaceuticals Co., Ltd.

$3.33 -$1.42 (-29.89%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$3.33
Day Range
$3.32$3.33
Year Range
$3.15$4.75
Market Cap
406.32M
AVG Volume
669
Trailing/Forward PE
77.23/1.05
PEG ratio
438.23
Dividend Yield
3.85%
Next Earnings Date
2026-10-28
Primary Exchange
Other OTCUS
Revenue (JPY) · TTM
020B40B60B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
JCRRF Revenue (JPY) · TTM by quarter
PeriodRevenue (JPY) · TTM
27 Q141.63B
26 Q432.06B
26 Q329.23B
26 Q229.45B
26 Q124.99B
25 Q433.07B
25 Q335.03B
25 Q235.26B
25 Q140.21B
24 Q442.87B
Net Income (JPY) · TTM
-10B-5B05B10B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
JCRRF Net Income (JPY) · TTM by quarter
PeriodNet Income (JPY) · TTM
27 Q1865.57M
26 Q42.21B
26 Q3-2.41B
26 Q2-2.33B
26 Q1-5.5B
25 Q4-4.76B
25 Q3-228M
25 Q2-435M
25 Q14.1B
24 Q45.51B
Operating Income (JPY) · TTM
-10B-5B05B10B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
JCRRF Operating Income (JPY) · TTM by quarter
PeriodOperating Income (JPY) · TTM
27 Q1-971.8M
26 Q41.11B
26 Q3-4.9B
26 Q2-2.93B
26 Q1-6.36B
25 Q4-6.86B
25 Q3-1.25B
25 Q2-319M
25 Q14.96B
24 Q47.53B
EBITDA (JPY) · TTM
-5B05B10B15B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
JCRRF EBITDA (JPY) · TTM by quarter
PeriodEBITDA (JPY) · TTM
27 Q14.17B
26 Q45.95B
26 Q3188.82M
26 Q2-15.75M
26 Q1-4.32B
25 Q4-3.3B
25 Q32.45B
25 Q23.56B
25 Q19.38B
24 Q410.72B
Cash Flows (JPY) · TTM
02B4B6B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
JCRRF Cash Flows (JPY) · TTM by quarter
PeriodCash Flows (JPY) · TTM
27 Q10
26 Q40
26 Q30
26 Q20
26 Q10
25 Q40
25 Q30
25 Q21.87B
25 Q13.52B
24 Q44.54B
EPS (JPY) · TTM
-50-250255024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
JCRRF EPS (JPY) · TTM by quarter
PeriodEPS (JPY) · TTM
27 Q17.1
26 Q418.14
26 Q3-19.72
26 Q2-19.07
26 Q1-44.98
25 Q4-38.89
25 Q3-1.85
25 Q2-3.52
25 Q132.68
24 Q443.92
Expenses (JPY) · TTM
020B40B60BR&DSG&A24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
JCRRF Expenses (JPY) · TTM by quarter
PeriodExpenses (JPY) · TTM
27 Q132.46B
26 Q429.81B
26 Q345.4B
26 Q243.48B
26 Q142.25B
25 Q441.79B
25 Q328.8B
25 Q228.21B
25 Q127.6B
24 Q428.89B
Shares Outstanding · TTM
-75M-50M-25M025M50M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
JCRRF Shares Outstanding · TTM by quarter
PeriodShares Outstanding · TTM
27 Q1-57M
26 Q4-57M
26 Q327M
26 Q20
26 Q10
25 Q40
25 Q30
25 Q20
25 Q10
24 Q40
Dividends (JPY)
00.020.040.060.08Sep 22Mar 23Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26Sep 26Mar 27
JCRRF Dividends (JPY) by quarter
PeriodDividends (JPY)
Mar 270.07
Sep 260.07
Mar 260.06
Sep 250.07
Mar 250.07
Sep 240.07
Mar 240.07
Sep 230.07
Mar 230.08
Sep 220.07
PE Ratio
1020304050med 28.46Mar 23Jun 23Oct 23May 24Aug 24Nov 24Sep 26
JCRRF PE Ratio by quarter
PeriodPE Ratio
Sep 2628.26
Sep 2628.66
Aug 2629.38
Aug 2629.09
Aug 2629.15
Aug 2628.86
Jul 2628.72
Jul 2629.88
Jul 2629.62
Jul 2629.49
Jul 2629.39
Dec 2421.96
Dec 2421.76
Dec 2421.37
Dec 2420.87
Nov 2420.83
Nov 2421.53
Nov 2421.47
Nov 2421.23
Nov 2421.28
Oct 2421.18
Oct 2420.8
Oct 2420.75
Oct 2420.69
Sep 2415.25
Sep 2415.43
Sep 2415.1
Sep 2415.26
Aug 2414.34
Aug 2414.17
Aug 2414.48
Aug 2414.39
Aug 2414.38
Jul 2415.09
Jul 2415.45
Jul 2418.82
Jul 2419.16
Jun 2419.53
Jun 2419.4
Jun 2419.11
Jun 2419.03
May 2419.09
May 2419.06
May 2418.9
May 2418.91
May 2418.57
Apr 2419.22
Apr 2418.77
Apr 2418.6
Apr 2431.88
Mar 2421.18
Mar 2421.19
Mar 2420.85
Feb 2421.06
Feb 2421.06
Feb 2421.01
Feb 2420.88
Oct 2342.62
Oct 2342.04
Oct 2342.11
Oct 2342.03
Oct 2341.94
Sep 2346.93
Sep 2346.48
Sep 2346.31
Sep 2346.29
Sep 2345.81
Aug 2345.85
Aug 2345.54
Aug 2345.4
Aug 2344.38
Jul 2344.22
Jul 2344.52
Jul 2343.54
Jul 2344.6
Jun 2345.29
Jun 2333.01
Jun 2336.94
Jun 2336.29
Jun 2336.44
May 2336.62
May 2335.92
May 2335.35
May 2335.11
Apr 2335.49
Apr 2334.93
Apr 2334.83
Apr 2334.32
Mar 2333.41
Mar 2327.06
Mar 2327.29
Mar 2327.96
Mar 2328.11
Feb 2333.63
Feb 2333.05
Feb 2332.38
Feb 2332.32
Jan 2349.69
Jan 2349.61
Jan 2348.96
Free Cash Flow Yield
0%2%4%6%med 0%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
JCRRF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 260%
Sep 260%
Aug 260%
Aug 260%
Aug 260%
Aug 260%
Jul 260%
Jul 260%
Jul 260%
Jul 260%
Jul 260%
Jun 260%
Jun 260%
Jun 260%
Jun 260%
May 260%
May 260%
May 260%
May 260%
May 260%
Apr 260%
Apr 260%
Apr 260%
Apr 260%
Mar 260%
Mar 260%
Mar 260%
Mar 260%
Feb 260%
Feb 260%
Feb 260%
Feb 260%
Jan 260%
Jan 260%
Jan 260%
Jan 260%
Jan 260%
Dec 250%
Dec 250%
Dec 250%
Dec 250%
Nov 250%
Nov 250%
Nov 250%
Nov 250%
Oct 250%
Oct 250%
Oct 250%
Oct 250%
Oct 250%
Sep 250%
Sep 250%
Sep 250%
Sep 250%
Aug 250%
Aug 250%
Aug 250%
Aug 250%
Aug 250%
Jul 250%
Jul 250%
Jul 250%
Jul 250%
Jun 250%
Jun 250%
Jun 250%
Jun 250%
May 250%
May 250%
May 250%
May 250%
May 250%
Apr 250%
Apr 250%
Apr 250%
Apr 250%
Mar 252.19%
Mar 252.2%
Mar 252.21%
Mar 252.22%
Feb 252.18%
Feb 252.2%
Feb 252.15%
Feb 252.17%
Jan 252.12%
Jan 252.1%
Jan 252.1%
Jan 252.08%
Jan 252.09%
Dec 243.91%
Dec 243.95%
Dec 244.02%
Dec 244.12%
Nov 244.12%
Nov 243.99%
Nov 244%
Nov 244.04%
Nov 244.04%
Oct 244.05%
Oct 244.13%
Price to Sales
1.522.533.5med 2.44Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
JCRRF Price to Sales by quarter
PeriodPrice to Sales
Sep 261.95
Sep 261.98
Aug 262.03
Aug 262.01
Aug 262.01
Aug 261.99
Jul 261.98
Jul 262.06
Jul 262.04
Jul 262.04
Jul 262.03
Jun 262.12
Jun 262.11
Jun 262.1
Jun 262.1
May 262.77
May 262.77
May 262.76
May 262.73
May 262.73
Apr 262.77
Apr 262.76
Apr 262.77
Apr 262.78
Mar 262.77
Mar 262.75
Mar 262.76
Mar 262.72
Feb 262.69
Feb 262.68
Feb 262.63
Feb 262.71
Jan 262.67
Jan 263.06
Jan 263.11
Jan 263.1
Jan 263.08
Dec 253.43
Dec 253.46
Dec 253.42
Dec 253.41
Nov 253.43
Nov 253.43
Nov 253.39
Nov 253.37
Oct 253.38
Oct 253.35
Oct 253.12
Oct 253.13
Oct 253.06
Sep 252.34
Sep 252.32
Sep 252.32
Sep 252.72
Aug 252.71
Aug 252.71
Aug 252.71
Aug 252.73
Aug 252.72
Jul 252.72
Jul 252.75
Jul 252.06
Jul 252.02
Jun 251.9
Jun 251.92
Jun 252.18
Jun 252.3
May 252.29
May 252.27
May 252.31
May 252.31
May 252.3
Apr 252.28
Apr 252.26
Apr 252.28
Apr 252.33
Mar 252.42
Mar 252.42
Mar 252.4
Mar 252.4
Feb 252.44
Feb 252.41
Feb 252.46
Feb 252.45
Jan 252.51
Jan 252.52
Jan 252.53
Jan 252.55
Jan 252.54
Dec 242.24
Dec 242.22
Dec 242.18
Dec 242.13
Nov 242.12
Nov 242.19
Nov 242.19
Nov 242.16
Nov 242.17
Oct 242.16
Oct 242.12
EV/EBITDA
0200400600800med 17.53Mar 24Jul 24Oct 24Jan 25May 25May 26Sep 26
JCRRF EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 2617.26
Sep 2617.41
Aug 2617.68
Aug 2617.57
Aug 2617.6
Aug 2617.49
Jul 2617.44
Jul 2617.87
Jul 2617.77
Jul 2617.72
Jul 2617.68
Jun 26523.96
Jun 26523.3
Jun 26520.92
Jun 26521.09
May 26624.92
May 26624.77
May 26623.54
May 26617.96
May 26618.96
Apr 26625.1
Apr 26623.19
Apr 26624.95
Apr 26625.89
Jun 2534.1
Jun 2534.37
Jun 2538.15
Jun 2539.83
May 2539.65
May 2539.31
May 2540.01
May 2539.95
May 2539.86
Apr 2539.56
Apr 2539.28
Apr 2539.51
Apr 2540.3
Mar 2526.89
Mar 2526.8
Mar 2526.69
Mar 2526.6
Feb 2527.01
Feb 2526.79
Feb 2527.28
Feb 2527.14
Jan 2527.74
Jan 2527.87
Jan 2527.92
Jan 2528.15
Jan 2528.08
Dec 2410.66
Dec 2410.57
Dec 2410.4
Dec 2410.18
Nov 2410.16
Nov 2410.47
Nov 2410.44
Nov 2410.34
Nov 2410.36
Oct 2410.32
Oct 2410.15
Oct 2410.12
Oct 2410.1
Sep 248.26
Sep 248.36
Sep 248.19
Sep 248.27
Aug 247.8
Aug 247.71
Aug 247.87
Aug 247.82
Aug 247.81
Jul 248.18
Jul 248.36
Jul 2410.09
Jul 2410.27
Jun 2410.21
Jun 2410.14
Jun 2410
Jun 249.96
May 249.99
May 249.97
May 249.89
May 249.9
May 249.73
Apr 2410.05
Apr 249.83
Apr 249.74
Apr 2416.37
Mar 2413.55
Mar 2413.56
Mar 2413.35
Feb 2413.48
Feb 2413.48
Feb 2413.45
Feb 2413.37
Oct 2324.01
Oct 2323.69
Oct 2323.73
Oct 2323.69
Price/Operating Cashflow
0100200300400med 41.66Mar 23Jul 23Oct 23May 24Aug 24Dec 24Mar 25
JCRRF Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Mar 2545.65
Mar 2545.49
Mar 2545.29
Mar 2545.11
Feb 2545.9
Feb 2545.47
Feb 2546.41
Feb 2546.13
Jan 2547.28
Jan 2547.52
Jan 2547.62
Jan 2548.05
Jan 2547.92
Dec 2425.57
Dec 2425.34
Dec 2424.89
Dec 2424.3
Nov 2424.26
Nov 2425.07
Nov 2425
Nov 2424.72
Nov 2424.78
Oct 2424.67
Oct 2424.22
Oct 2424.16
Oct 2424.09
Sep 2418.5
Sep 2418.72
Sep 2418.32
Sep 2418.51
Aug 2417.4
Aug 2417.18
Aug 2417.56
Aug 2417.45
Aug 2417.44
Jul 2418.3
Jul 2418.73
Jul 2422.82
Jul 2423.23
Jun 2418.6
Jun 2418.48
Jun 2418.2
Jun 2418.13
May 2418.19
May 2418.16
May 2418
May 2418.02
May 2417.69
Apr 2418.31
Apr 2417.88
Apr 2417.72
Apr 2430.37
Mar 2435.89
Mar 2435.9
Mar 2435.33
Feb 2435.69
Feb 2435.68
Feb 2435.61
Feb 2435.39
Oct 2341.91
Oct 2341.34
Oct 2341.4
Oct 2341.33
Oct 2341.24
Sep 2346.15
Sep 2357.29
Sep 2357.08
Sep 2357.06
Sep 2356.47
Aug 2356.52
Aug 2356.13
Aug 2355.97
Aug 2354.71
Jul 2354.5
Jul 2354.88
Jul 2353.67
Jul 2354.98
Jun 2355.83
Jun 2386.36
Jun 2396.66
Jun 2394.95
Jun 2395.33
May 2395.81
May 2393.97
May 2392.49
May 2391.86
Apr 2392.86
Apr 2391.37
Apr 2391.12
Apr 2389.78
Mar 2387.41
Mar 23173.57
Mar 23175.05
Mar 23179.34
Mar 23180.33
Feb 23215.71
Feb 23212.03
Feb 23207.73
Feb 23207.34
Jan 23318.76
Price to Book
0100200300med 1.58Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
JCRRF Price to Book by quarter
PeriodPrice to Book
Sep 261.31
Sep 261.33
Aug 261.36
Aug 261.35
Aug 261.35
Aug 261.34
Jul 261.33
Jul 261.39
Jul 261.38
Jul 261.37
Jul 261.37
Jun 261.32
Jun 261.32
Jun 261.31
Jun 261.31
May 261.73
May 261.73
May 261.73
May 261.7
May 261.71
Apr 261.73
Apr 261.72
Apr 261.73
Apr 261.73
Mar 26248.34
Mar 26246.72
Mar 26247.49
Mar 26244.47
Feb 26241.76
Feb 26240.25
Feb 26236.53
Feb 26243.59
Jan 26239.82
Jan 26274.93
Jan 26279.03
Jan 26278.77
Jan 26276.8
Dec 251.84
Dec 251.86
Dec 251.83
Dec 251.83
Nov 251.84
Nov 251.84
Nov 251.82
Nov 251.8
Oct 251.81
Oct 251.8
Oct 251.67
Oct 251.68
Oct 251.64
Sep 251.65
Sep 251.63
Sep 251.63
Sep 251.91
Aug 251.91
Aug 251.91
Aug 251.91
Aug 251.92
Aug 251.91
Jul 251.92
Jul 251.93
Jul 251.45
Jul 251.42
Jun 251.26
Jun 251.27
Jun 251.44
Jun 251.52
May 251.51
May 251.5
May 251.53
May 251.53
May 251.52
Apr 251.51
Apr 251.5
Apr 251.51
Apr 251.54
Mar 251.5
Mar 251.49
Mar 251.49
Mar 251.48
Feb 251.51
Feb 251.49
Feb 251.52
Feb 251.51
Jan 251.55
Jan 251.56
Jan 251.56
Jan 251.58
Jan 251.57
Dec 241.62
Dec 241.6
Dec 241.57
Dec 241.54
Nov 241.53
Nov 241.59
Nov 241.58
Nov 241.56
Nov 241.57
Oct 241.56
Oct 241.53
JCR Pharmaceuticals Co., Ltd.
JCRRF
Stockpicker

Video analysis: JCRRF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: JCRRF

MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

businesswire.com · 11 Sep 2026

MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

TOKYO & HYOGO, Japan--(BUSINESS WIRE)--JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.

JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

businesswire.com · 21 Jul 2026

JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in the United Arab Emirates.

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

businesswire.com · 17 Jun 2026

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease (AD), enabled by JCR's proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo®

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.